We are live on
!
Find out more
BI
BVF Inc Portfolio holdings
AUM
$3.14B
1-Year Est. Return
249.53%
This Fund
S&P 500
This Quarter
Est. Return
+64.47%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.47B
AUM Growth
-$332M
(-12%)
Cap. Flow
-$269M
Cap. Flow
% of AUM
-10.92%
Top 10 Holdings %
Top 10 Hldgs %
58.61%
Holding
50
New
6
Increased
9
Reduced
9
Closed
4
Top Buys
| 1 |
Nektar Therapeutics
NKTR
|
+$42.3M |
| 2 |
CDTX
Cidara Therapeutics
CDTX
|
+$40.1M |
| 3 |
ABVX
Abivax
ABVX
|
+$34.2M |
| 4 |
Structure Therapeutics
GPCR
|
+$28.5M |
| 5 |
Stoke Therapeutics
STOK
|
+$28.4M |
Top Sells
| 1 |
Axsome Therapeutics
AXSM
|
+$136M |
| 2 |
Celcuity
CELC
|
+$112M |
| 3 |
Mirum Pharmaceuticals
MIRM
|
+$80.5M |
| 4 |
Ionis Pharmaceuticals
IONS
|
+$75.6M |
| 5 |
Revolution Medicines
RVMD
|
+$39.4M |
Sector Composition
| 1 | Healthcare | 99.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Kymera Therapeutics
KYMR
$9.3B
| $311M | 12.63% |
5,502,710
| – | – |
|
|
2
Revolution Medicines
RVMD
$39.2B
| $186M | 7.52% |
3,974,913
-1,007,471
| -20% | -$39.4M |
|
3
Protagonist Therapeutics
PTGX
$8.75B
| $170M | 6.9% |
2,560,916
-650,125
| -20% | -$37M |
|
4
MoonLake Immunotherapeutics
MLTX
$1.63B
| $142M | 5.74% |
19,751,284
| – | – |
|
|
CDTX
5
DELISTED
Cidara Therapeutics
CDTX
| $135M | 5.49% |
1,414,165
+627,773
| +80% | +$40.1M |
|
6
GH Research
GHRS
$1.83B
| $126M | 5.12% |
8,827,712
| – | – |
|
|
7
Mirum Pharmaceuticals
MIRM
$7.3B
| $110M | 4.44% |
1,495,290
-1,266,043
| -46% | -$80.5M |
|
8
Xoma
XOMA
| $99.8M | 4.05% |
2,590,303
| – | – |
|
|
9
Structure Therapeutics
GPCR
$3.42B
| $89.7M | 3.64% |
3,203,917
+1,432,500
| +81% | +$28.5M |
|
10
Kura Oncology
KURA
$993M
| $76.3M | 3.09% |
8,617,162
+863,033
| +11% | +$6.15M |
|
|
SEPN
11
Septerna Inc
SEPN
$1.53B
| $75.5M | 3.06% |
4,015,790
-380,334
| -9% | -$4.99M |
|
|
PVLA
12
Palvella Therapeutics
PVLA
$2.19B
| $72.8M | 2.95% |
1,161,249
+464,694
| +67% | +$20.7M |
|
|
13
Nektar Therapeutics
NKTR
$2.29B
| $72.6M | 2.94% |
+1,276,595
| New | +$42.3M |
|
14
Zymeworks
ZYME
$1.81B
| $67.3M | 2.73% |
3,938,641
-370,294
| -9% | -$5.3M |
|
|
15
Axsome Therapeutics
AXSM
$12B
| $59.1M | 2.4% |
486,757
-1,203,464
| -71% | -$136M |
|
16
AC Immune
ACIU
$242M
| $57.3M | 2.32% |
19,822,436
| – | – |
|
17
Immunocore
IMCR
$1.72B
| $57.2M | 2.32% |
1,574,288
+550,000
| +54% | +$18.7M |
|
18
Olema Pharmaceuticals
OLMA
$1.02B
| $51.8M | 2.1% |
5,295,893
| – | – |
|
19
Tyra Biosciences
TYRA
$1.9B
| $51.1M | 2.07% |
3,649,794
-294,400
| -7% | -$3.36M |
|
|
ABVX
20
Abivax
ABVX
$11.7B
| $47.4M | 1.92% |
+558,031
| New | +$34.2M |
|
21
Monte Rosa Therapeutics
GLUE
$1.98B
| $41.9M | 1.7% |
5,660,132
| – | – |
|
22
4D Molecular Therapeutics
FDMT
$600M
| $40.2M | 1.63% |
4,629,289
| – | – |
|
|
23
Stoke Therapeutics
STOK
$1.83B
| $38.9M | 1.58% |
+1,657,096
| New | +$28.4M |
|
24
Cullinan Oncology
CGEM
$1.09B
| $34.1M | 1.38% |
5,750,683
| – | – |
|
|
25
Celcuity
CELC
$4.35B
| $32.5M | 1.32% |
658,421
-2,807,579
| -81% | -$112M |
|
Similar funds
GKWIM
BP
SC
AWE
EAM
HIMCH
SCM
AWM